This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ALGN Q1 Earnings and Revenues Top Estimates, Stock Up in After-market
by Zacks Equity Research
Align Technology reports first-quarter 2025 financial results, reflecting strength in the Imaging Systems & CAD/CAM Services business segment.
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
by Zacks Equity Research
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EMEA Growth & Product Launches to Support Boston Scientific Stock
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
by Zacks Equity Research
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
by Zacks Equity Research
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
HSIC Gears Up for Q1 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
by Zacks Equity Research
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
CHE Stock Falls Despite Q1 Earnings & Revenue Beat, Gross Margin Declines
by Zacks Equity Research
Chemed delivers first-quarter top-line growth across two of its segments, VITAS and Roto-Rooter.
Here's Why You Should Add Veeva Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand
by Zacks Equity Research
PEN reports better-than-expected earnings and revenues in the first quarter of 2025.
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market
by Zacks Equity Research
RMD's stellar third-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its business.
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised
by Zacks Equity Research
Edwards Lifesciences' first-quarter 2025 performance benefits from its differentiated portfolio of therapies to treat patients with structural heart disease.
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
by Zacks Equity Research
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
BSX Q1 Earnings & Revenues Beat, Stock Up, 2025 View Raised
by Zacks Equity Research
Boston Scientific's first-quarter 2025 performance benefits from the strength of its product portfolio.
Concentra Stock Slips Despite Deal to Acquire Pivot Onsite Innovations
by Zacks Equity Research
CON is set to acquire Pivot Onsite Innovations, expanding its onsite occupational health services and strengthening its national footprint in workforce health solutions.
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
DGX delivers solid top-line growth in the first quarter of 2025.
Zimmer Biomet to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZBH's Hips business is expected to have witnessed growth on the back of its suite of navigation solutions in direct anterior stems and surgical impactors.